All In Biotech

Drug Trial Radar · NCT04141423

Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil

An Open Label, Multiple Ascending Dose Trial in Patients With T1DM to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin Tregopil and to Evaluate the Postprandial Glucose Control With Different Meal Types in Comparison With Insulin Aspart

Last checked: Nov 20, 2026Latest source record: Jun 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

55

Actual

Start

Oct 28, 2019

Primary completion

Apr 23, 2021

Study completion Apr 23, 2021

Sponsor

Lead sponsor
Biocon LimitedIndustry
Sponsor type
Industry
Collaborators
Profil Institut für Stoffwechselforschung GmbH; Juvenile Diabetes Research Foundation
First posted
Oct 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-centre, open label, multiple ascending dose trial in patients with type 1 diabetes mellitus

Conditions

  • Type 1 Diabetes Mellitus (T1DM)

Interventions

  • TregopilDrug

    Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs)Time frame: Between screening (up to Day -21) and End of study ( up to Day 6)
  2. Laboratory safety parametersTime frame: Between screening (up to Day -21) and End of study ( up to Day 6)
  3. Physical examinationTime frame: Between screening (up to Day -21) and End of study ( up to Day 6)
  4. Vital signs, clinicallyTime frame: Between screening (up to Day -21) and End of study ( up to Day 6)
  5. Hypoglycaemic eventsTime frame: Between screening (up to Day -21) and End of study ( up to Day 6)
  6. Hyperglycaemia eventsTime frame: Between screening (up to Day -21) and End of study ( up to Day 6)
  7. ElectrocardiogramsTime frame: Between screening (up to Day -21) and End of Treatment ( up to Day 6)
  8. Adverse events (AEs)Time frame: Day of screening to Day 20 (Diary) and During follow up Via (Telephone)
  9. Hypoglycaemic eventsTime frame: Day of screening to Day 20 (Diary) and During follow up Via (Telephone)
  10. Hyperglycaemia eventsTime frame: Day of Run-in to Day 20 (Diary) and During follow up Via (Telephone)
  11. Laboratory safety parametersTime frame: Day of screening and Day 20
  12. Physical examinationTime frame: Day of screening, Dosing day 1 and Day 20
  13. Vital signsTime frame: Day of screening, Day1-6 and Day 20)
  14. ElectrocardiogramsTime frame: Day of screening and Day 20
  15. Anti-insulin Tregopil antibodiesTime frame: Day -1 and Day 20

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Profil Mainz GmbH & Co. KG Malakoff-Passage,Rheinstraße 4C D-55116

    Mainz, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.